Rheumatoid Arthritis

Although the obesity rate has been steadily increasing since the 1960s, with 1 in 3 adults currently classified as obese in the United States, Maria M. Wertli, MD, PhD, Research Fellow, Horten Centre for Patient Oriented Research and Knowledge Transfer, Department of Internal Medicine, University of Zurich, Switzerland, and colleagues assert that the impact of being overweight and obese on the working population is yet to be wholly realized.
Traditionally, patients with rheumatoid arthritis (RA) have been treated with immunosuppressive drugs, such as corticosteroids, disease-modifying antirheumatic drugs (DMARDs; eg, methotrexate), and nonsteroidal anti-inflammatory drugs, but in the last 1 to 2 decades, biologic DMARDs-consisting of several cytokine inhibitors and other immune modulators-have been added to this list.
A subanalysis of the Bristol-Myers Squibb-funded APPRAISE study suggests medium-or high-level ultrasonography can determine whether patients treated with the company's rheumatoid arthritis medication abatacept have an early response.
Q fever, caused by the bacterium Coxiella burnetii, is rare-approximately 40 cases are reported annually in the United States, and it occurs in <5% of patients with acute infection.
The strategy of treat-to-target (T2T) is paying off for patients with rheumatoid arthritis (RA) in daily clinical practice, according to a study presented at the 2015 annual meeting of the American College of Rheumatology (ACR).
Many patients with rheumatoid arthritis (RA) are not receiving appropriate management of cardiovascular risk factors, in particular, lipid testing and treatment of high cholesterol levels.
Although no biosimilar copy of a biologic therapy specific to rheumatoid arthritis (RA) has been approved by the US Food and Drug Administration, studies continue to be encouraging.
For patients withrheumatoid arthritis (RA) who do not have an adequate response to anti–tumor necrosis factor (anti-TNF) therapy, switching to another anti-TNF appears to be the wiser choice from both a health and an economic standpoint.
Reducing the dose of biologic in patients with rheumatoid arthritis (RA) is feasible, cost-effective, and does not appear to compromise clinical response, according to separate studies presented at the 2015 annual meeting of the European League Against Rheumatism (EULAR).
Tofacitinib does not appear to increase the risk for nonmelanoma skin cancer (NMSC), according to a safety review across the entire tofacitinib rheumatoid arthritis (RA) clinical program, which was presented at the 2015 annual meeting of the European League Against Rheumatism.
Page 5 of 9
Results 41 - 50 of 87
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology